Baseline Serum HMGB1 and the Composite of All-Cause Mortality or First Heart Failure Rehospitalization in Heart Failure with Preserved Ejection Fraction.

Authors

Haoran Chen, Xiaofei Miao, Liping Shen, Jin Han, Weizhang Li, Yukun Xu, Zhuo Chen, Lingyun Gu, Junyou Cui

Published in

Journal of inflammation research. Volume 19. Pages 633336. Epub Oct 13, 2026.

Abstract

To evaluate the association between baseline serum high mobility group box 1 (HMGB1) and the composite of all-cause mortality or first heart failure rehospitalization in patients with heart failure with preserved ejection fraction (HFpEF).
This single-center prospective cohort included 224 patients with HFpEF. The primary endpoint was the first occurrence of all-cause mortality or heart failure rehospitalization.
During a median observation time of 58 months, 37 of 224 patients (16.5%) experienced the composite endpoint. Baseline HMGB1 was higher in patients with events than in those without events (8.76 ± 3.18 vs 5.99 ± 1.86 µg/L; P<0.001). After adjustment for NT-proBNP, age, and sex, each 1 µg/L increase in HMGB1 was associated with a higher risk of the composite endpoint (hazard ratio, 1.399; 95% confidence interval [CI], 1.242-1.576; P<0.001). Apparent areas under the curve were 0.753 (95% CI, 0.653-0.853) for HMGB1, 0.790 (95% CI, 0.708-0.872) for NT-proBNP, and 0.870 (95% CI, 0.793-0.947) for their combination. The combination did not significantly outperform NT-proBNP alone (ΔAUC, 0.080; 95% CI, -0.012 to 0.171; nominal P=0.088; Holm-adjusted P=0.176). The optimism-corrected Cox concordance index was 0.828, and sensitivity analyses showed associations in the same direction.
Higher baseline serum HMGB1 was associated with the composite of all-cause mortality or first heart failure rehospitalization in this exploratory HFpEF cohort. Incremental discrimination beyond NT-proBNP and clinical utility remain unestablished. Independent prospective multicenter validation is required.

PMID:
42893241
Bibliographic data and abstract were imported from PubMed on 18 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.